SHB 1697
In CommitteeHouse
Newborn screening additions
Ensuring timely, efficient, and evidence-based additions to newborn screenings.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill streamlines how Washington adds new conditions to its newborn screening panel by requiring the state to adopt the federal recommended panel and follow a strict, time-bound process for evaluating and adding new conditions based on scientific evidence and feasibility. It also updates collection timelines, creates a dedicated revenue account for screening fees, and ensures public input is possible.
- Requires hospitals and providers to collect blood samples for newborn screening within 48 hours of birth (reduced from 48 hours — same number, but now explicitly clarified) and deliver samples to the state lab within 72 hours (excluding state lab closure days).
- Establishes a mandatory process for adding new conditions to the newborn screening panel: the state board of health must include all conditions on the federal recommended uniform screening panel as of January 1, 2025, and must review and decide on future federal additions within 12 months of their addition.
- Requires a feasibility review before adding any new condition, including analysis of costs, federal funding, impact on state health programs, and whether screening technology and treatments exist — this review must be completed before rulemaking.
- Creates a new 'newborn screening revenue account' to hold all fees collected for screening, with expenditures limited to activities directly related to implementing the screening program; only the Department of Health secretary (or designee) may authorize spending.
- Allows members of the public to formally request additions to the screening panel, and requires the state board of health to establish standards for evaluating such requests and conduct feasibility reviews for qualified petitions.
- Clarifies that all positive test results for conditions on the screening panel must be reported to the Department of Health, and removes outdated language about reporting other conditions at the board’s discretion.
Who is affected
- Newborn infants and their families — Newborns and their families benefit from earlier detection of rare but serious conditions, potentially preventing serious health complications or death; parents retain the right to decline screening for religious reasons.
- Hospitals and birthing facilities — Must follow updated procedures for collecting and submitting blood samples within strict timeframes (within 48 hours of birth, delivered to the state lab within 72 hours), and must report positive test results to the Department of Health.
- State Board of Health and Department of Health — Responsible for setting the official list of conditions tested in newborn screening, conducting feasibility reviews before adding new conditions, and managing the fee structure and implementation timeline.
- Health Care Authority — May be asked to provide input on how new screening additions would affect state-funded health programs like Medicaid (Apple Health) and other public health services.
- Public and advocacy groups (e.g., rare disease organizations) — Can request that new conditions be added to the screening panel, and may receive information or support related to conditions identified through screening.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Requires adoption of the federal recommended uniform screening panel as of January 1, 2025, ensuring Washington aligns with national best practices and evidence-based screening for 32+ conditions—dramatically improving early detection of rare but treatable metabolic and genetic disorders in newborns.
Public SafetyPeopleRef: Sec. 3(1)(b)Creates a dedicated newborn screening revenue account to hold all screening fees, ensuring fees are used exclusively for screening program costs (e.g., specialty clinics, sickle cell outreach), reducing risk of fund diversion and improving program accountability and sustainability.
FinancialPeopleRef: Sec. 6Mandates a 12-month deadline for deciding whether to add newly federal-recommended conditions, preventing indefinite delays and ensuring timely access to life-saving interventions for infants with conditions like SCID or MPS I.
Public SafetyPeopleRef: Sec. 3(2)Allows public petitioning for condition additions and requires feasibility reviews for qualified requests, increasing transparency and community engagement while still grounding decisions in scientific and economic analysis—balancing responsiveness with fiscal responsibility.
Public SafetyPeopleRef: Sec. 3(3)Explicitly preserves parental right to decline screening on religious grounds, reinforcing bodily autonomy and religious freedom while maintaining public health oversight.
Rights & LibertiesPeopleRef: Sec. 2(2)
Potential Concerns (5)
Mandates strict 48-hour and 72-hour timelines for blood sample collection and delivery, which could strain hospital and birthing facility logistics—especially in rural or under-resourced facilities with limited staffing or transport infrastructure—potentially increasing risk of sample degradation or missed screenings if timelines are not met.
Public SafetyRef: Sec. 2(1)-(2)Requires feasibility reviews—including cost analysis, federal funding assessment, and impact on state health programs—before adding new conditions, which adds administrative burden and delay to implementation, potentially slowing adoption of life-saving tests even when evidence supports them.
Business & EmploymentRef: Sec. 3(2)(a)Requires consultation with the Health Care Authority on impacts to Medicaid and other state health programs, but does not allocate additional funding for implementation, potentially shifting administrative and clinical workload to local providers and county health departments without reimbursement.
Local GovernmentRef: Sec. 3(2)(a)Excludes state lab closure days from the 72-hour delivery window, which may create ambiguity in rural areas where courier services are infrequent or unreliable, increasing risk of sample degradation and false negatives—particularly for time-sensitive conditions like PKU.
Public SafetyRef: Sec. 2(3)Allows public petitions for condition additions, but sets a high evidentiary bar (‘sufficient scientific evidence’) without defining the threshold, potentially leading to inconsistent or politically motivated petitions that strain limited feasibility review resources.
Public SafetyRef: Sec. 3(3)(a)
Who Is Most Affected
Infants benefit from faster, more consistent access to screening for emerging conditions (e.g., SCID, MPS I) as federal recommendations are automatically adopted, reducing diagnostic odysseys and improving outcomes. However, the 48/72-hour timeline may increase stress for families in rural or transportation-challenged areas if sample collection is delayed.
Hospitals and birthing facilities face new operational requirements (e.g., 48-hour draw, 72-hour delivery) and reporting obligations, increasing administrative burden and potential liability if deadlines are missed. However, the dedicated revenue account and fee structure help offset some costs.
The Department of Health and State Board of Health gain clearer authority and timelines for panel updates, improving program efficiency and reducing political interference. However, they must absorb added administrative costs for feasibility reviews and public petitions without new funding.
The Health Care Authority must provide input on impacts to Medicaid and other state health programs, potentially increasing staff workload. However, early identification of conditions reduces long-term Medicaid costs by enabling earlier, cheaper interventions.
Advocacy and rare disease groups gain formal petition rights and a transparent review process, empowering them to push for inclusion of underrepresented conditions. However, the high evidentiary bar and feasibility review timeline may slow progress for niche conditions with limited research.